

**SENATE BILL****No. 1014**

---

---

**Introduced by Senator Jackson**February 13, 2014

---

---

An act to add Section 4068.1 to the Business and Professions Code, to amend Section 117700 of, and to add Section 117670.1 to, the Health and Safety Code, and to add Article 3.4 (commencing with Section 47120) to Chapter 1 of Part 7 of Division 30 of the Public Resources Code, relating to pharmaceutical waste.

## LEGISLATIVE COUNSEL'S DIGEST

SB 1014, as introduced, Jackson. Pharmaceutical waste: home-generated.

(1) The Department of Resources Recycling and Recovery was required, pursuant to provisions repealed on January 1, 2013, to develop, in consultation with appropriate state, local, and federal agencies, model programs for the collection and proper disposal of drug waste.

This bill would enact the Home-Generated Pharmaceutical Waste Collection Disposal Act and would define terms for purposes of the act. The bill would require a producer of covered pharmaceuticals to submit to the Department of Resources Recycling and Recovery, by July 1, 2015, except as specified, a product stewardship plan and would authorize one or more producers to submit a plan or designate a stewardship organization to act as an agent on behalf of the producers to submit a plan. The bill would require the stewardship plan to contain specified elements with regard to the collection and disposal of home-generated pharmaceutical waste, including provisions for the payment of all administrative and operational fees associated with the product stewardship program.

The bill would specify procedures for the approval of the plan by the department and would require a producer, group of producers, or

stewardship organization operating a stewardship program to take specified actions with regard to the disposal of home-generated pharmaceutical waste and promoting product stewardship programs to consumers, pharmacists, retailers of covered pharmaceuticals, and health care practitioners.

The bill would require a producer, group of producers, or stewardship organization operating a product stewardship program to prepare and submit to the department an annual written report describing the program's activities during the previous calendar year by July 1, 2016, or at a later date as approved by the department, and on or before July 1 annually thereafter.

The bill would authorize the department to adopt regulations to implement the act and would require the department to adopt regulations to provide for the appropriate management of consolidated home-generated pharmaceutical waste, to establish a schedule of fees to be charged to cover the department's costs of administering and enforcing the act, and to adopt a schedule setting the amounts of administrative civil penalties that the department would be authorized to impose. The bill would require a producer, group of producers, or a stewardship organization submitting a plan to the department to pay the fees set by the department and would require the department to deposit the fees into the Home-Generated Pharmaceutical Waste Program Account, which the bill would create in the Integrated Waste Management Fund. The department would be authorized to expend the fees, upon appropriation by the Legislature, to administer and enforce the act.

The bill would authorize the department to issue an administrative order to, or impose a civil penalty upon, a producer who is in violation of the act or a regulation adopted pursuant to the act. The bill would require the department to deposit the penalties into the Home-Generated Pharmaceutical Waste Penalty Account, which the bill would create in the Integrated Waste Management Fund, and would authorize the department to expend the moneys in that account, upon appropriation by the Legislature, to enforce the act.

(2) The Medical Waste Management Act, administered by the State Department of Public Health, regulates the management and handling of medical waste, including pharmaceutical waste, as defined. Existing law defines the term medical waste and excludes certain types of waste from that definition.

This bill would define the term “home-generated pharmaceutical waste” for purposes of that act. The bill would exclude, from the definition of medical waste, home-generated pharmaceutical waste that is handled by a collection and disposal program operating in accordance with the act specified above. This exclusion would not become operative until the Secretary of State posts a notice regarding the effective date of the regulations that the department is required to adopt pursuant to that act.

(3) The Pharmacy Law provides for the licensure and regulation of pharmacists and pharmacy establishments by the California State Board of Pharmacy, and makes a knowing violation of that law a misdemeanor.

The bill would also authorize a pharmacy to accept the return of home-generated pharmaceutical waste from a consumer, consistent with specified federal laws. Because a knowing violation of this provision would be a crime, the bill would impose a state-mandated local program.

(4) The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.  
State-mandated local program: yes.

*The people of the State of California do enact as follows:*

1 SECTION 1. Section 4068.1 is added to the Business and  
2 Professions Code, to read:  
3 4068.1. A pharmacy may accept the return of home-generated  
4 pharmaceutical waste, as defined in Section 117670.1 of the Health  
5 and Safety Code, from a consumer, consistent with the Federal  
6 Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et seq.) and  
7 the Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).  
8 SEC. 2. Section 117670.1 is added to the Health and Safety  
9 Code, to read:  
10 117670.1. “Home-generated pharmaceutical waste” means a  
11 prescription or over-the-counter human or veterinary  
12 home-generated pharmaceutical, including, but not limited to, a  
13 drug, as defined in Section 109925 or in Section 321(g)(1) of Title  
14 21 of the United States Code, that is a waste, as defined in Section

1 25124, derived from a household, including, but not limited to, a  
2 multifamily residence or household.

3 SEC. 3. Section 117700 of the Health and Safety Code is  
4 amended to read:

5 117700. Medical waste does not include any of the following:

6 (a) Waste generated in food processing or biotechnology that  
7 does not contain an infectious agent as defined in Section 117675.

8 (b) Waste generated in biotechnology that does not contain  
9 human blood or blood products or animal blood or blood products  
10 suspected of being contaminated with infectious agents known to  
11 be communicable to humans.

12 (c) Urine, feces, saliva, sputum, nasal secretions, sweat, tears,  
13 or vomitus, unless it contains fluid blood, as provided in  
14 subdivision (d) of Section 117635.

15 (d) Waste which is not biohazardous, such as paper towels,  
16 paper products, articles containing nonfluid blood, and other  
17 medical solid waste products commonly found in the facilities of  
18 medical waste generators.

19 (e) Hazardous waste, radioactive waste, or household waste,  
20 including, but not limited to, home-generated sharps waste, as  
21 defined in Section 117671.

22 (f) Waste generated from normal and legal veterinarian,  
23 agricultural, and animal livestock management practices on a farm  
24 or ranch.

25 (g) *(1) Home-generated pharmaceutical waste, including, but  
26 not limited to, consolidated home-generated pharmaceutical waste,  
27 that is handled by a collection and disposal program operating in  
28 accordance with Article 3.4 (commencing with Section 47120) of  
29 Chapter 1 of Part 7 of Division 30 of the Public Resources Code.*

30 *(2) The Department of Resources Recycling and Recovery shall  
31 notify the Secretary of State of the effective date of the regulations  
32 adopted pursuant to subdivision (b) of Section 47129 of the Public  
33 Resources Code. The Secretary of State shall post this notification  
34 on its Internet Web site within 15 days after receiving that notice.*

35 *(3) Paragraph (1) shall not become operative until the Secretary  
36 of State posts the notice described in paragraph (2) on its Internet  
37 Web site.*

38 SEC. 4. Article 3.4 (commencing with Section 47120) is added  
39 to Chapter 1 of Part 7 of Division 30 of the Public Resources Code,  
40 to read:

1 Article 3.4. Home-Generated Pharmaceutical Waste Collection  
2 and Disposal

3  
4 47120. The Legislature hereby finds and declares all of the  
5 following:

6 (a) Prescription and nonprescription drugs successfully allow  
7 us to live longer, healthier, and more productive lives.

8 (b) The public, particularly children and the elderly, are at  
9 significant and unnecessary risk of poisoning due to improper or  
10 careless disposal of drugs and the illegal resale of drugs.

11 (c) Our source water for drinking water is being contaminated  
12 by unwanted, leftover, or expired drugs passing through our  
13 wastewater and treatment centers.

14 (d) There is no mandatory statewide drug stewardship program  
15 for unwanted drugs in California.

16 (e) It is the intent of the Legislature that all members of the  
17 supply chain work together to implement an effective program to  
18 maximize the collection and disposal of unused drugs in California.

19 47121. This article shall be known, and may be cited, as the  
20 “Home-Generated Pharmaceutical Waste Collection and Disposal  
21 Act.”

22 47122. For the purposes of this article, the following terms  
23 have the following meanings:

24 (a) “Consumer” means an individual purchaser or owner of a  
25 covered pharmaceutical. “Consumer” does not include a business,  
26 corporation, limited partnership, or an entity involved in a  
27 wholesale transaction between a distributor and retailer.

28 (b) “Controlled substance” means a substance listed in Chapter  
29 1 (commencing with Section 11053) of Division 10 of the Health  
30 and Safety Code, or in Section 812 of Title 21 of the United States  
31 Code or subject to Section 813 of Title 21 of the United States  
32 Code.

33 (c) “Cosmetic” means anything defined as a cosmetic in Section  
34 109900 of the Health and Safety Code.

35 (d) (1) “Covered pharmaceutical” means a prescription drug  
36 or an over-the-counter human or veterinary drug.

37 (2) “Covered pharmaceutical” does not include any of the  
38 following:

39 (A) A drug that is regulated pursuant to either of the following:

- 1 (i) The federal Resource Conservation and Recovery Act of  
2 1976, as amended (42 U.S.C. Sec. 6901 et seq.).
- 3 (ii) The Radiation Control Law (Chapter 8 (commencing with  
4 Section 114960) of Part 9) of Division 104 of the Health and Safety  
5 Code.
- 6 (B) A Vitamin or supplement.
- 7 (C) A herbal-based remedy or a homeopathic drug, product, or  
8 remedy.
- 9 (D) Cosmetics, soap, with or without germicidal agents, laundry  
10 detergent, bleach, household cleaning products, shampoos,  
11 sunscreens, toothpaste, lip balm, antiperspirants, or other personal  
12 care products that are regulated cosmetics under the Federal Food,  
13 Drug, and Cosmetic Act (21 U.S.C. Sec. 301 et seq).
- 14 (E) A drug for which a producer provides a take-back program  
15 as part of a Federal Food and Drug Administration managed risk  
16 evaluation and mitigation strategy (21 U.S.C. Sec. 355-1).
- 17 (F) A drug that is a biological product, as defined in subsection  
18 (h) of Section 600.3 of Title 21 of the Code of Federal Regulations,  
19 as it read on January 1, 2015, if the producer provides a take-back  
20 program.
- 21 (G) A pet pesticide product contained in a pet collar, powder,  
22 shampoo, topical application, or other delivery system.
- 23 (e) “Drug” means anything defined as a drug in Section 109925  
24 of the Health and Safety Code or in Section 321 (g)(1) of Title 21  
25 of the United States Code.
- 26 (f) “Home-generated pharmaceutical waste” means a covered  
27 pharmaceutical that is a waste, as defined in Section 25124 of the  
28 Health and Safety Code, derived from a household, including, but  
29 not limited to, a multifamily residence or household.
- 30 (g) “Mail-back program” means a system whereby a generator  
31 of home-generated pharmaceutical waste may obtain a prepaid  
32 and preaddressed mailing envelope in which to place  
33 home-generated pharmaceutical waste for shipment to an entity  
34 that will dispose of it safely and legally.
- 35 (h) “Over-the-counter drug” means a drug that may be lawfully  
36 sold without a prescription.
- 37 (i) “Pharmaceutical wholesaler” means a person that sells or  
38 distributes covered pharmaceuticals for resale to an entity other  
39 than a consumer.

1 (j) “Plan” or “product stewardship plan” means a product  
2 stewardship plan to implement a program to collect and dispose  
3 of home-generated pharmaceutical waste.

4 (k) “Prescription drug” means a drug required by federal or state  
5 law to be dispensed lawfully only on prescription.

6 (l) (1) “Producer” shall be determined with regard to a covered  
7 pharmaceutical that is sold, offered for sale, or distributed in the  
8 state as meaning one of the following:

9 (A) The person that manufactures a covered pharmaceutical  
10 and that sells, offers for sale, or distributes that covered  
11 pharmaceutical in the state under that person’s own name or brand.

12 (B) If there is no person who meets the condition specified in  
13 subparagraph (A), the producer of the covered pharmaceutical is  
14 the owner or licensee of a trademark or brand under which the  
15 covered pharmaceutical is sold or distributed in California, whether  
16 or not the trademark is registered.

17 (C) If there is no person who meets the conditions specified in  
18 subparagraph (A) or (B), the producer of that covered  
19 pharmaceutical is the person who brings the pharmaceutical into  
20 the state for sale or distribution.

21 (2) “Producer” does not include either of the following:

22 (A) A retailer that puts its store label on a covered  
23 pharmaceutical.

24 (B) A pharmacist who dispenses prescription drugs to, or  
25 compounds a prescribed individual drug product for, a consumer.

26 (m) “Product stewardship program” or “program” means a  
27 program financed and operated by one or more producers to collect,  
28 transport, and dispose of home-generated pharmaceutical waste.

29 (n) “Stewardship organization” means an organization  
30 designated by a group of producers to act as an agent on behalf of  
31 each producer to operate a product stewardship program.

32 47124. (a) On or before July 1, 2015, or on a later date that  
33 may be specified by the department, a producer shall submit to the  
34 department a product stewardship plan that complies with the  
35 requirements of subdivision (b). One or more producers may submit  
36 a plan or designate a stewardship organization to act as an agent  
37 on behalf of the producers to submit a plan. A producer that  
38 designates a stewardship organization shall enter into an agreement  
39 with that stewardship organization to operate, on the producer’s  
40 behalf, a product stewardship program and the stewardship

1 organization shall submit a plan pursuant to this section on or  
2 before July 1, 2015, or on a later date that may be specified by the  
3 department.

4 (b) A product stewardship plan shall contain all of the following  
5 elements:

6 (1) A certification that the product stewardship program will  
7 accept all home-generated pharmaceutical waste that results from  
8 a covered pharmaceutical sold by the producer, or by the producers  
9 that enter into agreement with the stewardship organization, from  
10 all households, including multifamily households, unless excused  
11 from this requirement by the department as part of the approval  
12 of the plan.

13 (2) Contact information for the producer submitting the plan or  
14 for each of the producers participating in the product stewardship  
15 program submitting the plan.

16 (3) A description of the methods by which home-generated  
17 pharmaceutical waste will be collected and an explanation of how  
18 the collection system will conveniently and adequately serve the  
19 residents of the state.

20 (4) A description of how the product stewardship plan will  
21 provide collection services for home-generated pharmaceutical  
22 waste in all areas of that state that are convenient to the public and  
23 adequate to meet the needs of the population in the area being  
24 served.

25 (5) The location of each collection site and locations where  
26 envelopes for a mail-back program are available, if applicable.

27 (6) A list containing the name, location, permit status, and record  
28 of any penalties, violations, or regulatory orders received in the  
29 previous five years by each person that will be involved in  
30 transporting home-generated pharmaceutical waste and each  
31 medical waste disposal facility proposed to participate in the  
32 product stewardship program.

33 (7) A description of how the home-generated pharmaceutical  
34 waste will be safely and securely tracked and handled from  
35 collection through final disposal and the policies and procedures  
36 to be followed to ensure security.

37 (8) A description of how the public education and outreach  
38 activities required by subdivision (c) of Section 47126 will be  
39 implemented and how the effectiveness of those activities will be  
40 evaluated.

1 (9) A description of how the scope and extent of the product  
2 stewardship program are reasonably related to the amount of  
3 covered pharmaceuticals that are sold in the state by the producer  
4 or group of producers.

5 (10) A starting date when the collection of home-generated  
6 pharmaceutical waste will begin.

7 (11) A description of how support will be provided to any law  
8 enforcement agencies within the state that have, or later agree to  
9 have, a collection program for controlled substances, including all  
10 of the following:

11 (A) The provision of a collection kiosk with appropriate  
12 accessories and signage.

13 (B) An ability to accept controlled substances and other  
14 home-generated covered pharmaceutical waste.

15 (C) Technical support, including an appropriate person to  
16 provide onsite assistance with the sorting and separation of  
17 controlled substances at no cost to a participating law enforcement  
18 agency.

19 (12) A description of how collection sites for home-generated  
20 pharmaceutical waste may be placed at appropriate retail stores in  
21 the state, including a description of the involvement of the retail  
22 stores.

23 (13) If more than one producer will be involved in a proposed  
24 product stewardship program, the product stewardship plan for  
25 that program shall include a fair and reasonable manner for  
26 allocating the costs of the program among the participants in that  
27 program, so that the portion of costs paid by each producer is  
28 reasonably related to the amount of covered pharmaceutical sold  
29 by the producer in the state.

30 (14) (A) Provisions for the payment of all administrative and  
31 operational fees associated with the product stewardship program,  
32 including the cost of collecting, transporting, and disposing of  
33 home-generated pharmaceutical waste and the recycling or  
34 disposal, or both, of packaging collected with the home-generated  
35 pharmaceutical waste.

36 (B) The plan shall not allow a person or producer to charge a  
37 specific point-of-sale fee to consumers to recoup the costs of their  
38 product stewardship program, or charge a specific  
39 point-of-collection fee at the time the home-generated  
40 pharmaceutical waste is collected or delivered for disposal.

1 47125. (a) A producer, group of producers, or stewardship  
2 organization shall not collect home-generated pharmaceutical  
3 waste until it has received written approval of its product  
4 stewardship plan from the department.  
5 (b) Within 180 days after receipt and review of a product  
6 stewardship plan, the department shall conduct a noticed public  
7 hearing and determine whether the plan complies with the  
8 requirements of this article and any regulations adopted pursuant  
9 to this article. As part of its approval, the department may set  
10 reasonable performance goals for the program proposed to be  
11 implemented by the plan.  
12 (c) The department shall notify the applicant in writing of the  
13 approval of the plan.  
14 (d) If the department rejects a plan, it shall notify the applicant  
15 in writing of its reasons for rejecting the plan. The department may  
16 reject a plan without conducting a public hearing, other than the  
17 hearing required by subdivision (b).  
18 (e) An applicant whose plan has been rejected by the department  
19 shall submit a revised plan to the department within 60 days after  
20 receiving notice of the rejection. The department may require the  
21 submission of a further revised plan or may develop, approve, and  
22 impose its own product stewardship plan or an approved plan  
23 submitted by other producers pursuant to this article. The  
24 department shall present the imposed plan at a public hearing. The  
25 department is not required, and nothing in this article shall be  
26 interpreted as requiring the department, to create or impose a  
27 product stewardship plan.  
28 (f) If the department rejects a revised product stewardship plan  
29 or any other subsequently revised plan, a producer that is subject  
30 to the plan shall be considered to be out of compliance with this  
31 article and subject to the enforcement provisions contained in this  
32 article. If the department imposes its own plan, the producer shall  
33 not be considered out of compliance with this article if the producer  
34 complies with that plan.  
35 (g) At least every three years, a producer, group of producers,  
36 or stewardship organization operating a product stewardship  
37 program shall update the product stewardship plan and submit the  
38 updated plan to the department for review and approval.

1 (h) Any proposed changes to a product stewardship plan shall  
2 be submitted in writing to the department and approved by the  
3 department in writing prior to implementation of any change.

4 (i) On and after July 1, 2015, a producer who commences to  
5 sell a covered pharmaceutical in the state shall submit a product  
6 stewardship plan to the department or provide evidence of having  
7 joined an existing approved product stewardship program no later  
8 than 180 days after the date the producer commences to sell that  
9 covered pharmaceutical, following the producer's initial sale of  
10 the offer for sale of a covered pharmaceutical.

11 47126. A producer, group of producers, or stewardship  
12 organization operating a stewardship program shall comply with  
13 all local, state, and federal laws and regulations applicable to its  
14 operations, including laws and regulations governing the disposal  
15 of medical waste and controlled substances, and shall additionally  
16 take all of the following actions when operating the program:

17 (a) (1) Dispose of all home-generated pharmaceutical waste,  
18 in accordance with paragraph (1) of subdivision (a) of Section  
19 118215 of the Health and Safety Code.

20 (2) A producer or stewardship organization operating a  
21 stewardship program may petition the department for approval to  
22 use a final disposal technology, if lawful, that provides superior  
23 environmental and human health protection than provided by  
24 current medical waste disposal technology for covered  
25 pharmaceuticals, if and when the technology is proven and  
26 available. The department may approve that technology, if it  
27 provides equivalent protection in each, and superior protection in  
28 one or more, of the following areas:

29 (A) Monitoring of any emissions or waste.

30 (B) Worker health and safety.

31 (C) Air, water, or land emissions contributing to persistent,  
32 bioaccumulative, or toxic pollution.

33 (D) Overall impact on the environment and human health.

34 (b) Encourage the separation of home-generated pharmaceutical  
35 waste from its original containers, when appropriate, prior to  
36 collection or disposal.

37 (c) Promote the product stewardship program to consumers,  
38 pharmacists, retailers of covered pharmaceuticals, and health care  
39 practitioners as to the proper and safe method to dispose of

1 home-generated pharmaceutical waste, in accordance with the  
2 following:

3 (1) Develop and update as necessary, educational and other  
4 outreach materials aimed at retailers of covered pharmaceuticals.  
5 These materials may include, but are not limited to, one or more  
6 of the following:

7 (A) Signage that is prominently displayed and easily visible to  
8 the consumer.

9 (B) Written materials and templates of materials for reproduction  
10 by retailers to be provided to the consumer at the time of purchase  
11 or delivery, or both.

12 (C) Advertising or other promotional materials related to the  
13 product stewardship program.

14 (2) Prepare education and outreach materials that publicize the  
15 location and operation of collection locations in the state and  
16 disseminate the materials to health care facilities, pharmacies, and  
17 other interested parties.

18 (3) Establish an Internet Web site publicizing collection  
19 locations and program operations and a toll-free telephone number  
20 that residential generators can call to find nearby collection  
21 locations and understand how the program works.

22 47127. On or before July 1, 2016, or at a later date as approved  
23 in writing by the department, and on or before July 1 annually  
24 thereafter, a producer, group of producers, or stewardship  
25 organization operating a product stewardship program shall prepare  
26 and submit to the department an annual written report describing  
27 the program's activities during the previous calendar year. The  
28 report shall include all of the following information:

29 (a) A list of producers participating in the product stewardship  
30 program.

31 (b) The amount, by weight, of home-generated pharmaceutical  
32 waste collected at each drop-off site and in the entire state and, if  
33 applicable, the total amount by weight collected by a mail-back  
34 program.

35 (c) A description of the collection system, including the location  
36 of each collection site and if applicable, locations where envelopes  
37 for a mail-back program are provided.

38 (d) The name and location of disposal facilities at which  
39 home-generated pharmaceutical waste were disposed of and the

1 weight of home-generated pharmaceutical waste collected from  
2 residential generators disposed of at each facility.

3 (e) Whether policies and procedures for collecting, transporting,  
4 and disposing of home-generated pharmaceutical waste, as  
5 established in the plan, were followed during the previous calendar  
6 year and a description of any noncompliance.

7 (f) Whether any safety or security problems occurred during  
8 collection, transportation, or disposal of home-generated  
9 pharmaceutical waste during the previous calendar year and, if so,  
10 what changes have been or will be made to policies, procedures,  
11 or tracking mechanisms to alleviate the problem and to improve  
12 safety and security.

13 (g) A description of public education and outreach activities  
14 implemented during the reporting period, including the  
15 methodology used to evaluate the outreach and program activities.

16 (h) How the product stewardship program complied with all  
17 other elements in the product stewardship plan approved by the  
18 department, including its degree of success in meeting any  
19 performance goals set by the department as part of the approval  
20 of the plan.

21 (i) Any other information that the department may reasonably  
22 require.

23 47128. The department shall provide on its Internet Web site  
24 a list of all producers participating in product stewardship programs  
25 approved by the department and a list of all producers the  
26 department has identified as noncompliant with this article or the  
27 regulations adopted pursuant to this article.

28 47129. (a) The department may adopt regulations to implement  
29 this article.

30 (b) The department shall adopt regulations to do all of the  
31 following:

32 (1) Provide for the appropriate management of consolidated  
33 home-generated pharmaceutical waste to ensure public and  
34 environmental safety, including, but not limited to, handling,  
35 storage, containment, tracking, transportation, and disposal.

36 (2) Establish a schedule of fees to be charged to the producers  
37 to cover the department's costs of administering and enforcing  
38 this article. In setting the fee schedule, the department shall only  
39 recover its actual costs of administration and enforcement under

1 this article and shall not charge any amounts under this article in  
2 excess of its actual administrative and enforcement costs.

3 (3) Adopt a schedule setting the amounts of administrative civil  
4 penalties that the department may impose pursuant to Section  
5 47130, based on the nature, extent, and severity of the violation  
6 and any other relevant factors.

7 (c) A producer, group of producers, or a stewardship  
8 organization submitting a plan to the department shall pay the fees  
9 set by the department pursuant to subdivision (b).

10 (d) The department shall deposit all fees collected pursuant to  
11 this section into the Home-Generated Pharmaceutical Waste  
12 Program Account, which is hereby created in the Integrated Waste  
13 Management Fund. Upon appropriation by the Legislature, moneys  
14 deposited into the account may be expended by the department to  
15 administer and enforce this article.

16 47130. (a) The department may issue an administrative order  
17 to, or impose an administrative civil penalty upon, a producer who  
18 is in violation of this article or a regulation adopted pursuant to  
19 this article, to require compliance with this article or the regulation.

20 (b) The department shall deposit all penalties collected pursuant  
21 to this article into the Home-Generated Pharmaceutical Waste  
22 Penalty Account, which is hereby created in the Integrated Waste  
23 Management Fund. Upon appropriation by the Legislature, moneys  
24 deposited into the account may be expended by the department to  
25 enforce this article.

26 47134. This article does not require a retailer to host a  
27 collection site and nothing in this article shall be interpreted as  
28 requiring this participation.

29 47135. A producer or stewardship organization that creates  
30 and operates a plan that is approved by the department is not in  
31 violation of the Cartwright Act (Chapter 2 (commencing with  
32 Section 16700) of Part 2 of Division 7 of the Business and  
33 Professions Code), the Unfair Practices Act (Chapter 4  
34 (commencing with Section 17000) of Part 2 of Division 7 of the  
35 Business and Professions Code), or the Unfair Competition Law  
36 (Chapter 5 (commencing with Section 17200) of Part 2 of Division  
37 7 of the Business and Professions Code), with regard to actions  
38 that are taken in accordance with the plan or this article.

39 SEC. 5. No reimbursement is required by this act pursuant to  
40 Section 6 of Article XIII B of the California Constitution because

1 the only costs that may be incurred by a local agency or school  
2 district will be incurred because this act creates a new crime or  
3 infraction, eliminates a crime or infraction, or changes the penalty  
4 for a crime or infraction, within the meaning of Section 17556 of  
5 the Government Code, or changes the definition of a crime within  
6 the meaning of Section 6 of Article XIII B of the California  
7 Constitution.

O

March 10, 2014

Senator Hannah-Beth Jackson  
State Capitol, Room 5080  
Sacramento, CA 95814  
Sent by Fax: (916) 651-4919

**SUBJECT: SENATE BILL 1014 (JACKSON) – SAFE MEDICATION DISPOSAL – SUPPORT**

Dear Senator Jackson,

The County of Santa Barbara strongly supports Senate Bill (SB) 1014 (Jackson), which will require producers of pharmaceuticals, as defined, to create, finance, and manage an extended producer responsibility (EPR) system for California consumers to safely and conveniently dispose of expired and unwanted pharmaceuticals. The County supported last year's pharmaceuticals EPR bill, SB 727, which was held in Committee, and believes that this is an issue that must be addressed at the statewide level.

Prescription drug abuse in California has skyrocketed in recent years, as have hospitalizations for overdoses. These abused pharmaceuticals are most often stolen from the medicine cabinets of friends and relatives, and this epidemic has led to an increase in crime in many communities in California and across the nation.

For too long, local government, by default, has carried the burden of financing and managing pharmaceutical take-back programs, broadly financed by taxpayers or utility ratepayers. Despite these efforts, pharmaceuticals are either being stockpiled in medicine cabinets, a prime target for drug abusers; or flushed down the toilet, threatening our water quality, as even the most advanced wastewater treatment processes cannot remove these pharmaceutical compounds from the water. It is time for the producers that make and profit from pharmaceuticals to share in the responsibility of properly managing this dangerous and problematic waste.

Santa Barbara County developed its own household pharmaceutical collection program, Operation Medicine Cabinet, in January 2010. Jointly managed by the Public Works Department and Sheriff's Office, the program collects literally tons of medications each year. Last year, approximately 5,200 pounds were collected from the public. Due to overwhelming use, the Sheriff's Office has had to increase the frequency of servicing the collection boxes, in some locations up to once daily. In Sheriff's staff time alone, the program costs the County nearly \$154,000 annually.

SB 1014 is the right solution because it creates a privately managed and financed system to allow consumers to properly and conveniently dispose of their unwanted pharmaceuticals. It uses a free-market approach that allows manufacturers to design the program in whichever way is most cost effective for them, with minimal oversight from state regulators.

SB 1014 will ultimately lead to less illegal diversion, reduce the ongoing pharmaceutical drug abuse epidemic in California, and reduce the environmental impacts of pharmaceuticals in waterways, by simply making it easier and more convenient for consumers to empty their medicine cabinets of unwanted and unused pharmaceuticals. For these reasons, the County of Santa Barbara strongly supports SB 1014.

If you have any questions about our position, please contact Leslie Robinson with our Public Works Department at (805) 882-3615 or [lrobins@cosbpw.net](mailto:lrobins@cosbpw.net).

Sincerely,

Steve Lavagnino,  
Chair, Board of Supervisors

cc: Senator Kevin de Leon, fax: (916) 651-4922  
Senator Jerry Hill, fax: (916) 651-4913  
Senator Tony Strickland, fax: (805) 965-0701  
Assemblymember Das Williams, fax: (805) 564-1651  
Heidi Sanborn, California Product Stewardship Council, email: [heidi@calpsc.org](mailto:heidi@calpsc.org)